B
BioAegis Therapeutics
pGSN Protein Replacement Therapy | BioAegis Therapeutics
About BioAegis Therapeutics
BioAegis Therapeutics is a pioneering biotechnology company focused on developing plasma gelsolin protein replacement therapy to enhance the innate immune system. The company targets patients suffering from severe infections, including antibiotic-resistant strains, and aims to reduce mortality rates associated with these conditions. Operating in the healthcare and biotechnology market, BioAegis Therapeutics manufactures recombinant human plasma gelsolin, which is identical to the natural human protein, ensuring minimal side effects. This therapy is unique as it boosts the immune system without causing immunosuppression, making it a safer alternative to traditional treatments. The business model revolves around research and development, clinical trials, and eventual commercialization of their proprietary therapy. Revenue is generated through partnerships, licensing agreements, and future sales of their therapeutic products.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2011
- Headquarters
- North Brunswick Township, United States
- Employees
- 14
- Open positions
- None listed
- Dealroom signal
- 76.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Diabetes, Biotechnology, Oncology, Nutrition, Immune System, Spinout, Alternative Protein, Macro-Nutrients, Biotech and Pharma, proteomics
- Business model
- Manufacturing
- Client focus
- b2c
Latest news
Press, funding announcements and product moves mentioning BioAegis Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Mar 2022 | $22M | $88M | Undisclosed | ↗ |
| EARLY VC✓Equity / VC | Aug 2018 | $4.1M | $16M | Undisclosed | — |
Growth signals
Latest recorded traffic for BioAegis Therapeutics is 1.5K monthly website visits, up 7.1% over the last three months. BioAegis Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors3 additional known investors
Brigham and Women's Hospital
Harvard University
DRIVe - Division of Research, Innovation, and Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about BioAegis Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BioAegis Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.